Moderna's Trading Volume Plummets 55.68% Ranking 199th as FDA Data Requests Delay Vaccine Approval

On May 21, 2025, Moderna's trading volume reached $466 million, a significant decrease of 55.68% from the previous day, ranking 199th in the day's stock market activity. Moderna's stock price fell by 7.82%.

Moderna has voluntarily withdrawn its pending approval application for a combination flu/COVID vaccine, citing the need for more clinical data. The company plans to resubmit the application later this year after gathering additional information. This decision comes after the FDA requested more data this month, leading Moderna to prioritize the mRNA-1083 vaccine for older adults at higher risk. The initial Biologics License Application (BLA) filing took place in early 2025.

In a related development, Moderna has also withdrawn the Biologics License Application (BLA) for mRNA-1083, its combination flu/COVID vaccine candidate. The company announced that it will resubmit the BLA later this year, following the completion of the ongoing Phase 3 trial of its investigational seasonal influenza vaccine. This move is part of Moderna's strategy to ensure the efficacy and safety of its vaccines before seeking regulatory approval.